Trade Mark Journal No.2026/031 31 July 2026

WO0000001928727 (5)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:11 June 2026
Date of designation in the UK: 11 June 2026
Image for mark 1928727_TIF NYLASPEG

International priority date claimed: 12 January 2026 (European Union Intellectual Property Office (EUIPO)) (019301853)
Class 5
Pharmaceutical products; pharmaceutical preparations; pharmaceutical products for neutropenia treatment; pharmaceutical products for reducing the duration of neutropenia and the incidence of febrile neutropenia; pharmaceutical products for treatment of hematological diseases and conditions; pharmaceutical products for treatment of oncological diseases and conditions; pharmaceutical products for treatment of immunological diseases and conditions; pharmaceutical products for treatment of side effects in patients treated with chemotherapy.

QILU Pharma Spain, S.L.

Representative: ABG INTELLECTUAL PROPERTY, Avenida de Burgos, 16D, 4ª planta,, Edificio Euromor, E-28036 Madrid, SPAIN